Pfizer (PFE)

You'd need to invest over $200,000 in the pharma leader at its current price.

Pfizer's dividend yield is attractive, but investors need to know if it can maintain it.

Some look like bargains, but others could be value traps.

Verizon and Pfizer pay generous dividends, and each has a different path to growth. Here's how income investors can lock in yield before year-end.

AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.

A reliable payout, a growing cancer treatment lineup, and improving guidance make this drugmaker worth a second look right now.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...

Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.

PJP's one-year return beats RSPH's, but RSPH offers broader diversification across 61 healthcare holdings at a lower expense ratio.

You'll need to generate $12,000 a year in dividends to average $1k per month from Amgen, Pfizer, J&J, AbbVie, and Bristol Myers Squibb.

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

The sell-offs for both of these beaten-down biotech stocks appear to be overdone.

Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.

Grail and Veeva Systems could be well insulated from near-term headwinds.

Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.

The company is entering what could be a particularly challenging period.

D-Wave is growing revenue at nearly 180% while Rigetti trades at a lower valuation, but both burn cash heavily and face unproven commercial roadmaps.

Buffett thinks many stocks are too hot to touch right now, but these three aren't.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

A couple of the stocks on this list pay more than 6% in dividends.

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.